SCHEMBL7124256

SCHEMBL7124256

Cc1ncc(-c2cccc(Nc3ncc4c(Cl)cc(C(F)(F)F)cn34)c2)n1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 2/20 0.36
ATP1A1 P05023 1/20 0.36
ATP1B1 P05026 1/20 0.36
ATP1A3 P13637 1/20 0.36
ATP1B2 P14415 1/20 0.36
ATP1A2 P50993 1/20 0.36
ATP1B3 P54709 1/20 0.36
FXYD2 P54710 1/20 0.36
ATP1A4 Q13733 1/20 0.36
DYRK1A Q13627 3/20 0.35
FGFR3 P22607 4/20 0.35
KDR P35968 4/20 0.35
CTSC P53634 2/20 0.35
TP53 P04637 2/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
FYN P06241 3/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23554063 0.72 CCNA2 (0.44) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL7129837 0.72 ALDH1A1 (0.41) TTKATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL7118472 0.69 EGFR (0.55) TP53MAPT
SCHEMBL7125607 0.69 ALDH1A1 (0.47) FGFR3KDRGAAMAPTFYN
SCHEMBL7128686 0.67 RIPK2 (0.47) TP53MAPT
SCHEMBL7120305 0.66 KDR (0.60) KDR
SCHEMBL7127650 0.66 MAPT (0.46) TTKDYRK1AKDRTP53GAA
SCHEMBL6754387 0.65 MAOB (0.58) DYRK1AMAPTGSK3B
SCHEMBL6754391 0.65 MAOB (0.58) DYRK1AMAPTGSK3B
SCHEMBL6756952 0.64 MAOB (0.46) DYRK1AFGFR3KDRGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 TTK 1660/4885ATP1A1 1225/4885ATP1B1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.